MBIO - MUSTANG BIO, INC.
IEX Last Trade
0.18
-0.003 -1.889%
Share volume: 1,914
Last Updated: Fri 27 Dec 2024 08:29:47 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.18
0.00
-1.85%
Fundamental analysis
19%
Profitability
8%
Dept financing
6%
Liquidity
50%
Performance
25%
Performance
5 Days
7.32%
1 Month
-7.37%
3 Months
-23.48%
6 Months
-62.55%
1 Year
-86.77%
2 Year
-96.60%
Key data
Stock price
$0.18
DAY RANGE
$0.18 - $0.19
52 WEEK RANGE
$0.14 - $1.53
52 WEEK CHANGE
-$86.96
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Manuel Litchman
Region: US
Website: mustangbio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: mustangbio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition.
Recent news